Tesla
TSLA
MicroStrategy
MSTR
MARA Holdings
MARA
Apple
AAPL
Microsoft
MSFT
US Stock MarketDetailed Quotes
TCRX TScan Therapeutics
- 2.850
- -0.170-5.63%
Close Dec 13 16:00 ET
- 2.850
- 0.0000.00%
Post 16:00 ET
152.11MMarket Cap-3.00P/E (TTM)
3.100High2.820Low705.24KVolume3.030Open3.020Pre Close2.06MTurnover2.19%Turnover RatioLossP/E (Static)53.37MShares9.69052wk High0.66P/B92.00MFloat Cap2.60052wk Low--Dividend TTM32.28MShs Float14.710Historical High--Div YieldTTM9.27%Amplitude1.450Historical Low2.914Avg Price1Lot Size
About TScan Therapeutics Company
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
Company Profile
SymbolTCRX
Company NameTScan Therapeutics
Listing DateJul 16, 2021
Issue Price15.00
Founded2018
CEODr. Gavin MacBeath, PhD
MarketNASDAQ
Employees154
Fiscal Year Ends12-31
Address830 Winter Street
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02451
Phone1-857-399-9500
Websitehttp://www.tscan.com
Company Executives
- Name
- Position
- Salary
- Dr. Gavin MacBeath, PhD
- Chief Executive Officer and Director
- 3.20M
- Dr. Zoran Zdraveski
- Chief Legal and Strategy Officer and Secretary
- 1.58M
- Dr. Chrystal U. Louis, M.D.
- Chief Medical Officer
- --
- Jason A. Amello
- Treasurer, Chief Financial Officer and Principal Accounting Officer
- --
- Leiden Dworak
- Vice President, Finance
- --
- Dr. Stephen R. Biggar,M.D.,PhD
- Chairman of the Board
- 123.17K
- Garry A. Nicholson
- Independent Director
- --
- Dr. Gabriela Gruia, M.D.
- Independent Director
- 113.53K
- Robert Keith Woods
- Independent Director
- 90.90K
- Dr. Barbara Klencke, M.D.
- Independent Director
- 121.74K
- Katina Dorton, J.D.,M.B.A.
- Independent Director
- 132.59K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.